Changing the course of Alzheimer's disease: Emerging disease modifying therapies

Current Psychiatry Reviews

Volumn 2, Issue 2, 2006, Pages 179-188

  Christensen, Daniel D ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Alzheimer's disease; Amyloid; Disease modifying

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIDEPRESSANT AGENT; ATORVASTATIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; CHOLINESTERASE INHIBITOR; DONEPEZIL; FLURBIPROFEN 4 NITROXYBUTYL ESTER; GALANTAMINE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; HOMOTAURINE; LEVO FLURBIPROFEN; LY 450139; M 266; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERAMEXANE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PROTEIN INHIBITOR; RIVASTIGMINE; TACRINE; TAU PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; AGITATION; ALZHEIMER DISEASE; CLINICAL STUDY; CLINICAL TRIAL; COGNITION; COST OF ILLNESS; DEMENTIA; DISEASE COURSE; DRUG BINDING SITE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; ECONOMIC EVALUATION; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HUMAN; MENINGOENCEPHALITIS; MOOD DISORDER; NEPHROTOXICITY; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN SYNTHESIS INHIBITION; PSYCHOSIS; REVIEW; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY;

EID: 33746014948     PISSN: 15734005     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340006776875978     Document Type: Review

References (105)

1. Cummings JL. Alzheimer's disease. N Engl J Med 2004; 351: 56-67.
2. Hebert LE, Scherr PA, Scherr JL, Bienias JL, Bennett DA, Evans DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-1122.
3. Leon J, Cheng C-K, Neumann PJ. Alzheimer's disease care: costs and potential savings. Health Affairs 1998; 35: 771-791.
4. Guralnik JM, Yanagishita M, Schneider EL. Projecting the older population of the United States: lessons from the past and prospects for the future. Milbank Quarterly 1988; 66: 283-308.
5. Manton KG, Singer BH, Suzman RM. The scientific and policy needs for improved health forecasting models for elderly populations. In: Manton KG, Singer BH, Suzman RM Ed, Forecasting the Health of Elderly Populations. New York: Springer-Verlag, 1993; 3-35.
6. Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 677-685.
7. Farlow M, Gracon SI, Hershey LA, et al. A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268: 2523-2529.
8. Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Ann Rev Pharmacol Toxicol 2003; 43: 545-584.
9. Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003; 306: 821-827.
10. Davis KL, Thal LJ, Gamzu ER, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327: 1253-1259.
11. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized, controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-991.
12. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589-595.
13. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, the Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease. A 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998; 158: 1021-1031.
14. Rösler M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ 1999; 318: 633-640.
15. Wilcock GK, Lilienfield S, Gaens E, the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000; 321: 1-7.
16. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-495.
17. Farlow M, Anand R, Messina J Jr, Hartman R, Veach J. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000; 44: 236-241.
18. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2002; 72: 310-314.
19. Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001; 57: 481-488.
20. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet 2004; 363: 2105-2115.
21. Krishnan KRR, Charles HC, Doraiswamy PM, et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003; 160: 2003-2011.
22. Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005; 162: 676-682.
23. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ, the Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-1341.
24. Rogawski MA. What is the rationale for new treatment strategies in Alzheimer's disease? CNS Spectrums 2004; 9 (suppl 5): 6-12,31.
25. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil. A randomized controlled trial. JAMA 2004; 291: 317-324.
26. Anonymous. Forest announces that neramexane did not demonstrate statistical significance in recently completed Phase III trial in patients with moderate to severe Alzheimer's disease. Press release; August 31, 2004. http://www.frx.com/news/PressRelease-Archive.aspx Accessed June 20, 2005.
27. Sloane PD, Zimmerman S, Suchindran C, et al. The public health impact of Alzheimer's disease, 2000-2050: Potential implication of treatment advances. Annu Rev Public Health 2002; 23: 213-231.
28. Fagnani F, Lafuma A, Pechevis M, et al. Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications. Dement Geriatr Cogn Disord 2004; 17: 5-13.
29. Feldman H, Gauthier S, Hecker J, et al. Economic evaluation of donepezil in moderate to severe Alzheimer's disease. Neurology 2004; 63: 644-650.
30. Marin D, Amaya K, Casciano R, et al. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease. Int Psychogeriatr 2003; 15: 385-398.
31. Lu S, Hill J, Fillit H. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study. Am J Geriatr Pharmacother 2005: 3: 92-102.
32. Fillit HM. The pharmacoeconomics of Alzheimer's disease. Am J Manag Care 2000; 6: S1139-S1148.
33. Neumann PJ, Hermann RC, Kuntz KM, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999; 52: 1138-1145.
34. Klein WL, Krafft GA, Finch CE. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 2001; 24: 219-224.
35. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001; 32: 177-180.
36. Gandy S, Martins RN, Buxbaum J. Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2003; 17: 259-266.
37. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-356.
38. Oddo S, Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-421.
39. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43: 321-332.
40. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. PNAS 2005; 102: 6990-6995.
41. Blesch A, Tuszynski MH. Gene therapy and cell transplantation for Alzheimer's disease and spinal cord injury. Yonsei Med J 2004; 45(suppl): 28-31.
42. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 2005; 11: 551-555.
43. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173-177.
44. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000; 408: 979-982.
45. Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408: 982-985.
46. Gelinas DS, DaSilva K, Fenili D, St George-Hyslop P, McLaurin J. Immunotherapy for Alzheimer's disease. PNAS 2004; 101(suppl 2): 14657-14662.
47. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46-54.
48. Robinson SR, Bishop GM, Lee HG, Munch G. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 2004; 25: 609-615.
49. Hock C, Konietzko U, Streffer JR, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38: 547-554.
50. Fox NC, Black RS, Gilman S, et al. Effects of A-beta immunotherapy (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64: 1563-1572.
51. Gilman S, Koller M, Black RS, et al. Clinical effects of A immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64: 1553-1562.
52. Heppner FL, Gandy S, McLaurin J. Current concepts and future prospects for Alzheimer disease vaccines. Alzheimer Dis Assoc Disord 2004; 18: 38-43.
53. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 2003; 9: 448-452.
54. V717F transgenic mice reduces neuritic plaque. Neurobiol Aging 2004; 25: 587.
55. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. PNAS 2001; 98: 8850-8855.
56. Relkin N, Szabo P, Adamiak B, et al. Intravenous immunoglobulin (IVIg) treatment causes dose-dependent alterations in B-Amyloid (AB) levels and anti-AB antibody titers in plasma and cerebrospinal fluid (csf) of Alzheimer's Disease (AD) patients. Neurology 2005; 64(supplement 1): A144.
57. Serneels L, Dejaegere T, Craessaerts K, et al. Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Proc Natl Acad Sci USA 2005; 102: 1719-17124. Epub 2005 Jan 21.
58. Shen J, Bronson RT, Chen DF, Xia W, Selkoe DJ, Tonegawa S. Skeletal and CNS defects in presenilin-1-deficient mice. Cell 1997; 89: 629-639.
59. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004; 279: 12876-12882.
60. Wang Y, Chan SL, Miele L, et al. Involvement of Notch signaling in hippocampal synaptic plasticity. PNAS 2004; 101: 9458-9462.
61. Saura CA, Choi S-Y, Beglopoulos V, et al. Loss of presenilin function causes impairments of memory and synaptic plasticity followed by age-dependent neurodegeneration. Neuron 2004; 42: 23-36.
62. Hadland BK, Manley NR, Su D-M, et al. γ-Secretase inhibitors repress thymocyte development. PNAS 2001; 98: 7487-7491.
63. Barten DM, Guss VL, Corsa JA, et al. Dynamics of β-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic ice treated with a γ-secretase inhibitor. J Pharmacol Exp Ther 2005; 312: 635-643.
64. Siemers E, Dean RA, Satterhite J, et al. Safety, tolerability and changes in plasma and cerebrospinal fluid amyloid beta concentrations after administration of a functional gamma-secretase inhibitor in healthy volunteers. Presented at the 9th International Conference on Alzheimer's Disease and Related Disorders. Philadelphia, PA; July 21, 2004.
65. Siemers E. Effect of LY450139, a functional γ-secretase inhibitor, on plasma and cerebrospinal fluid concentrations of Aβ and cognitive functioning in patients with mild to moderate Alzheimer's disease. Presented at the 56h Annual Meeting of the American Academy of Neurology. San Francisco, CA; April 27, 2004.
66. Luo Y, Bolon B, Damore MA, et al. BACE1 (beta-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time. Neurobiol Dis 2003; 14: 81-88.
67. Wong P. BACE. Alzheimer's & Dementia 2005; 1 (suppl 1): S3.
68. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH. Aβ42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 2003; 278: 30748-30754.
69. Beher D, Clarke EE, Wrigley JD, et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem 2004; 279: 43419-4341926.
70. Lleo A, Berezovska O, Herl L, et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med 2004; 10: 1065-1066.
71. Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J Clin Invest 2003; 112: 440-449.
72. Golde TE, Eriksen J, Nicolle M, et al. Selective Abeta42 modifying agents: effects on Abeta deposition and behavior in Tg2576 mice. Presented at the 9th International Conference on Alzheimer's Disease and Related Disorders. Philadelphia, PA; July 18, 2004.
73. Galasko D, Graff-Radford N, Murphy MP, et al. Safety, tolerability, pharmacokinetics and A levels following short-term administration of R-flurbiprofen in healthy elderly individuals: a Phase I study. Presented at the 9th International Conference on Alzheimer's Disease and Related Disorders. Philadelphia, PA; July 18, 2004.
74. Wilcock G, Black S, Haworth J, et al. A placebo-controlled, double-blind trial of the selective Aβ-42 lowering agent, Flurizan (MPC-7869, R-flurbiprofen) in patients with mild to moderate Alzheimer's disease. Presented at the Alzheimer's Association International Conference on Prevention of Alzheimer's Disease. Washington, DC: June, 2005.
75. Ritchie CW, Bush AI, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (Clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease. Arch Neurol 2003; 60: 1685-1691.
76. Gervais F, Chalifour R, Garceau D, et al. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid 2001; 8 (suppl 1): 28-35.
77. Garceau D, Gurbindo C, Laurin J. Safety, tolerability and pharmacokinetic profile of Alzhemed™, an anti-amyloid agent for Alzheimer's disease, in healthy subjects. Presented at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. Geneva, Switzerland; April 3-6, 2002.
78. Geerts H. NC-531 Neurochem. Curr Opin Investig Drugs 2004; 5: 95-100.
79. Aisen P, Mehran M, Poole R, et al. Clinical data on Alzehemed after 12 months of treatment in patients with mild to moderate Alzheimer's disease. Presented at the 9th International Conference on Alzheimer's Disease and Related Disorders. Philadelphia, PA; July 18, 2004.
80. Gibson GL, Douraghi-Zadeh D, Parsons RB, Austen BM. Properties of ovine colostrinin (O-CLN) on the in vitro aggregation and toxicity of β-amyloid. Neurobiol Aging 2004; 25: 592.
81. Bilikiewicz A, Gaus W. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J Alzheimer's Dis 2004; 6: 17-26.
82. Leszek J, Inglot AD, Janusz M, et al. Colostrinin proline-rich polypeptide complex from ovine colostrum - a long-term study of its efficacy in Alzheimer's disease. Med Sci Monit 2002; 8: 193-196.
83. Treiber C, Simons A, Strauss M, et al. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J Biol Chem 2004; 279: 51958-51964.
84. Shaw KTY, Utsuki T, Rogers J, et al. Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. PNAS 2001; 98: 7605-7610.
85. Winblad B. The efficacy of phenserine in the treatment of mild-to-moderate Alzheimer's disease. Presented at the 7th International Conference on Alzheimer's Disease and Parkinson's Disease. Sorrento, Italy: March, 2005.
86. Citron M. β-Secretase inhibition for the treatment of Alzheimer's disease - promise and challenge. Trends Pharmacol Sci 2004; 25: 92-97.
87. Pedrini S, Causevic M, Carter T, et al. Statin-activated α-cleavage of Alzheimer amyloid precursor is modulated by rho/rock pathway. Program No. 441.18 2004 Abstract Viewer/Itinerary Planner. Washington, DC: Society for Neuroscience, 2004. Online.
88. Sparks DL, Sabbagh MN, Connor DJ, et al. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62: 753-757.
89. in't Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345: 1515-1521.
90. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 1996; 47: 425-432.
91. Szekely CA, Thorne JE, Zandi PP, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004; 23: 159-169.
92. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression. A randomized controlled trial. JAMA 2003; 289: 2819-2826.
93. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-1611.
94. Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst Rev 2002; (2): CD003673.
95. Couzin J. Clinical trials. Halt of Celebrex study threatens drug's future, other trials. Science 2004; 306: 2170.
96. Reines SA, Block GA, Morris JC, et al. on behalf of the Rofecoxib Protocol 091 Study Group. No effect on Alzheimer's disease in 1 1-year, randomized, blinded, controlled study. Neurology 2004; 62: 66-71.
97. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005; Mar 2: epub ahead of print.
98. in't Veld BA, Launer LJ, Breteler MM, Hofman A, Stricker BH. Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence. Epidemiol Rev 2002; 24: 248-268.
99. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 2001; 414: 212-216.
100. Martin BK, Meinert CL, Breitner JC. Double placebo design in a prevention trial for Alzheimer's disease. Controlled Clin Trials 2002; 23: 93-99.
101. Hauss-Wegrzyniak B, Vraniak P, Wenk GL. The effects of a novel NSAID on chronic neuroinflammation are age dependent. Neurobiol Aging 1999; 20: 305-313.
102. Van Groen T, Kadish I. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res Brain Res Rev 2005; 48: 370-378.
103. Anonymous. NicOx announces successful Phase I clinical results with HCT 1026 in development for Alzheimer's disease. Press release May 13, 2003. http://www.nicox.com/upload/HCT%-201026%20Final%20English.pdf Accessed May 16, 2005.
104. Fiorucci S, Santucci L, Sardina M, et al. Effect of HCT1026, a nitric oxide (NO) releasing derivative of flurbiprofen, on gastrointestinal mucosa: a double blind placebo-controlled endoscopic study. Presented at Digestive Disease Week. Orlando, FL; May 17-22, 2003.
105. Selkoe D. The amyloid hypothesis. Available at: www.alzforum. org/res/ adh/cur/knowntheamyloidcascade.asp Accessed July 5, 2005.